Time of infliximab therapy initiation and dose escalation in Crohn’s disease

Table 2 Univariate and multivariate analysis of clinical variables on infliximab

Variable	n	Requiring dose escalation within 12 mo	Fisher’s exact test P value	Log-rank test P value
Sex			0.58	0.91
Male	24	41.7%
Female	30	33.3%
Age at diagnosis			1.00	0.72
< 17 yr	11	36.4%
17-40 yr	36	36.1%
> 40 yr	6	33.3%
Disease behavior			0.91	1.00
Non-stricturing, non-penetrating	24	37.5%
Stricturing	9	44.4%
Penetrating	9	33.3%
Penetrating (perianal)	11	27.3%
Years between diagnosis and therapy initiation			0.31	0.11
< 2 yr	12	50.0%
≥ 2 yr	41	31.7%
Concurrent immunosuppressant therapy			0.16	0.09
No	27	48.1%
Yes	26	26.9%